In Silico Analysis of Laccifer Lacca as a Potential Therapeutic Agent for Cervical, Breast and Lung Cancers
Laccifer lacca has generally been used as pigmenting, coloring agent and dying in chemical industry. Although, it has wide range of industrial applications, but inappropriately, due to lesser availability of data, it has been ignored. Keeping in mind, the wide application of Laccifer lacca, we tried to report the in-silico anti-cancer effects. The experimental techniques used to determine the structure was X-RAY diffraction. The reported resolution of this entry is 2.80 Å. Percentile scores (ranging between 0-100) for global authentication metrics of the record. In silico have a good pool to explore various parameters in molecular docking. We have performed in silico analysis of the active components of Laccifer lacca against the cervical, breast and lung cancer proteins and also found that lac extract enhances the production of anti-inflammatory markers and the increase is significant when compared to the standard vinblastine. It has been demonstrated by Lala and colleagues that a short lived molecule nitric oxide can result in the progression of human tumours. Therefore, the prominent antioxidant activity of phytochemical that can act as inhibitors of nitric oxide production can act as anticancer therapeutics. Both methanolic and aqueous extract shows significant anticancer effect on the hela, MCF-7 & A549 cells suggesting them as potential anticancer therapeutics for future.
Keywords: Laccifer lacca, In-vitro & In-silico analysis, Carcinogenesis, Anti-inflammatory, Molecular Docking.
2. Prasad N, Agarwal S C. A convenient method for isolation of jalaric and aleuritic acids from shellac. Res. Ind., 1990; 35(3):164–166.
3. Ha C Y, Wang D X. Studies on the composition of domestic lac resin. Chem. Ind. For. Prod., 1992; 12(1):43–48.
4. Altstadt T.G., Fairchild C.R., Golik J., Johnston K.A., Kadow J.F., Lee F.Y., Long B.H., Rose W.C., Vyas D.M., Wong H., Wu M.J. and Wittman M.D. Synthesis and antitumor activity of novel C-7 paclitaxel ethers: discovery of BMS-184476. Journal of Medicinal Chemistry, 2001; 44(26):4577-4583.
5. Balunas M.J. and Kinghorn A.D. Drug discovery from medicinal plants. Life Sciences, 2005; 78(5):431-441.
6. Choy H., Safran H., Akerley W., Graziano S.L., Bogart, J.A. and Cole, B.F. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small-cell lung cancer. Clinical Cancer Research, 1998; 4(8):1931-1936.
7. Christian M.C., Pluda J.M., Ho T.C., Arbuck S.G., Murgo A.J. and Sausville, E.A. Promising new agents under development by division of cancer treatment, diagnosis, and centers of the National Cancer Institute. Seminars in Oncology, 1997; 24(2):219-40
8. Cichewitz R.H. and Kouzi S.A. Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection. Medicinal Research Reviews, 2004; 24(1):90-114.
9. Cisternino S., Bourasset F., Archimbaud Y., Semiond D., Sanderink G. and Scherrmann J.M. Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. British Journal of Pharmacology, 2003; 138(7):1367-1375.
10. Cragg G.M. and Newman D.J. Plants as source of anticancer agents. Journal of Ethno pharmacology, 2005; 100(1-2):72-79.
11. Jimtaisong A, Janthadee R & Nakrit T, In vitro antioxidant activities of laccaic acids and its aluminum lake, Food Sci. Biotechnol., 2013; 22(4):1055-1061.
12. Cragg G.M., Newman D.J. and Snader K.M. Natural products in drug discovery and development. Journal of Natural Products, 1997; 60(1):52-60.
13. Dhanamani M., Lakshmi Devi S. and Kannan S. Ethnomedicinal plants for cancer therapy- A review. Hygeia-Journal for Drugs and Medicines, 2011; 3(1):1-10.
14. Doorbar J. Molecular biology of human papilloma virus infection and cervical cancer. Clinical Science, 2006; 110(5):525–541.
15. Hartwell J.L. Plants used against cancer: a survey. 1971; 34(2):204-55.
16. Hwang B.Y., Su B.N., Chai H., Mi Q., Kardono L.B., Afriastini J.J., Riswan S., Santarsiero, B.D., Mesecar, A.D., Wild, R., Fairchild, C.R., Vite, G.D., Rose, W.C., Farnsworth, N.R., Cordell, G.A., Pezzuto, J.M., Swanson, S.M. and Kinghorn, A.D. Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaila silvestris. Journal of Organic Chemistry, 2004; 69(10):3350-3358.
17. Itokawa H., Wang X. and Lee K.H. Homoharringtonine and related compounds. In: Cragg, G.M., Kingston, D.G.I. and Newman, D. (eds). Anticancer agents from natural products, 2005; 47-70.
18. Kantarjian H.M., O’Brien S., Anderlini P. and Talpaz M. Treatment of chronic myelogenous leukemia: current status and investigational options. Blood, 1996; 87(8):3069-3081.
19. Kappor L.D. Handbook of ayurvedic medicinal plants, CRC press, Boca Raton, Florida. 1990; 416-17.
20. Kelland L.R. Flavopiridol the first cyclic-dependent kinase inhibitor to enter the clinic: current status. Expert Opinion on Investigational Drugs, 2000; 9(12):2903-2911.
21. Mastalerz H., Cook D., Fairchild C.R., Hansel S., Johnson W., Kadow J.F., Long B.H., Rose W.C., Tarrant J., Wu, M.J., Xue, M.Q., Zhang, G., Zoeckler, M. and Vyas, D.M. The discovery of BMS-275183: an orally efficacious novel taxane. Bioorganic Medicinal Chemistry, 2003; 11(20):4315-4323.
22. Nicoletti M.I., Colombo T., Rossi C., Monardo C., Stura S., M. Zucchetti A. Riva P. Morazzoni M. B. Donati E. Bombardelli M., D’Incalci M. and Giavazzi, R. IDN5109, A taxane with oral bioavailability and potent antitumor activity. Cancer Research, 2000; 60(4):842-846.
23. Parkin D.M. The global health burden of infection-associated cancers in the year 2002. International Journal of Cancer, 2006; 118(12):3030–3044.
24. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, CA: A Cancer Journal for Clinicians, 2005; 55(1):74-108.
25. Patwardhan, B., A.D.B. Vaidya, A.D.B. and Chorghade, M. Ayurveda and natural products drug discovery. Current Science, 2004; 86(6):789-799.
26. Polizzi D., Pratesi G., Monestiroli S., Tortoreto M., Zunino F., Bombardelli E., Riva A., Morazzoni P., Colombo T., D’Incalci T. and Zucchetti M. Oral efficacy and bioavailability of a novel taxane. Clinical Cancer Research, 2000; 6(5):2070-2074.
27. Powell, R.G., Weisleder, D., Smith, C.R. and Rohwedder, W.K. Structures of harringtonine, isoharringtonine, and homo-harringtonine. Tetrahedron Letters, 1970; 11(11):815-818.
28. Premalatha B. and Rajgopal G. Cancerian ayurvedic perspective. Pharmacological Research, 2005; 51(1):19-30.
29. Rao G.V., Kumar S., Islam M. and Mansour S.E. Folk medicines for anticancer therapy- a current status. Cancer Therapy, 1999; 6(10):913-922.
30. Geraghty R J, Capes-Davis A, Davis J M. Guidelines for the use of cell lines in biomedical research. Br J. Cancer, 2014; 111(6):1021-46
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).